Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2008 1
2010 1
2011 1
2012 4
2013 2
2014 1
2015 3
2016 2
2017 3
2018 5
2019 3
2020 7
2021 11
2022 10
2023 11
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Howard JF Jr, Bresch S, Genge A, Hewamadduma C, Hinton J, Hussain Y, Juntas-Morales R, Kaminski HJ, Maniaol A, Mantegazza R, Masuda M, Sivakumar K, Śmiłowski M, Utsugisawa K, Vu T, Weiss MD, Zajda M, Boroojerdi B, Brock M, de la Borderie G, Duda PW, Lowcock R, Vanderkelen M, Leite MI; RAISE Study Team. Howard JF Jr, et al. Lancet Neurol. 2023 May;22(5):395-406. doi: 10.1016/S1474-4422(23)00080-7. Lancet Neurol. 2023. PMID: 37059508 Clinical Trial.
Current drug treatment of myasthenia gravis.
Vanoli F, Mantegazza R. Vanoli F, et al. Curr Opin Neurol. 2023 Oct 1;36(5):410-415. doi: 10.1097/WCO.0000000000001196. Epub 2023 Aug 30. Curr Opin Neurol. 2023. PMID: 37678337 Review.
Ravulizumab for the treatment of myasthenia gravis.
Vanoli F, Mantegazza R. Vanoli F, et al. Expert Opin Biol Ther. 2023 Mar;23(3):235-241. doi: 10.1080/14712598.2023.2185131. Epub 2023 Mar 8. Expert Opin Biol Ther. 2023. PMID: 36852670 Clinical Trial.
Efgartigimod improves triple-negative myasthenia gravis.
Frangiamore R, Rinaldi E, Vanoli F, Andreetta F, Mantegazza R, Antozzi C. Frangiamore R, et al. Among authors: vanoli f. Neurol Sci. 2024 Mar;45(3):1307-1309. doi: 10.1007/s10072-023-07122-y. Epub 2023 Oct 24. Neurol Sci. 2024. PMID: 37875596 No abstract available.
Distinct pathways of homologous recombination controlled by the SWS1-SWSAP1-SPIDR complex.
Prakash R, Sandoval T, Morati F, Zagelbaum JA, Lim PX, White T, Taylor B, Wang R, Desclos ECB, Sullivan MR, Rein HL, Bernstein KA, Krawczyk PM, Gautier J, Modesti M, Vanoli F, Jasin M. Prakash R, et al. Among authors: vanoli f. Nat Commun. 2021 Jul 12;12(1):4255. doi: 10.1038/s41467-021-24205-6. Nat Commun. 2021. PMID: 34253720 Free PMC article.
miRNA in spinal muscular atrophy pathogenesis and therapy.
Magri F, Vanoli F, Corti S. Magri F, et al. Among authors: vanoli f. J Cell Mol Med. 2018 Feb;22(2):755-767. doi: 10.1111/jcmm.13450. Epub 2017 Nov 21. J Cell Mol Med. 2018. PMID: 29160009 Free PMC article. Review.
Complement Inhibition for the Treatment of Myasthenia Gravis.
Mantegazza R, Vanoli F, Frangiamore R, Cavalcante P. Mantegazza R, et al. Among authors: vanoli f. Immunotargets Ther. 2020 Dec 15;9:317-331. doi: 10.2147/ITT.S261414. eCollection 2020. Immunotargets Ther. 2020. PMID: 33365280 Free PMC article. Review.
59 results